Novo Nordisk | NVO - Net Income


Novo Nordisk reported DKK4.03B in Net Income for its fiscal quarter ending in June of 2025.





Net Income Change Date
ANI Pharmaceuticals USD 29.49M 2.86M Mar/2026
Aurora Cannabis CAD -71.1M 72.92M Mar/2026
Bausch Health Companies USD -1.42B 1.31B Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Canopy Growth CAD -157.11M 94.49M Mar/2026
Corcept Therapeutics USD -31.76M 56.05M Mar/2026
Drreddys Laboratories INR 2.21B 9.89B Mar/2026
Eli Lilly USD 7.4B 760M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Merck USD -4.24B 7.2B Mar/2026
Nektar Therapeutics USD -36.08M 978K Dec/2025
Novartis USD 3.16B 747M Mar/2026
Novo Nordisk DKK 26.89B 388M Dec/2025
Novo Nordisk DKK 4.03B 25.01B Jun/2025
Pacira USD 2.92M 1.28M Mar/2026
Perrigo USD -398.6M 1.02B Mar/2026
Phibro Animal Health USD 27.46M 932K Dec/2025
Prestige Brands USD 46.7M 22.44M Dec/2025
Sanofi EUR 1.61B 2.42B Mar/2026
Supernus Pharmaceuticals USD -2.29M 1.81M Mar/2026
Zoetis USD 601M 2M Mar/2026